Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decline in Short Interest

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 564,000 shares, a decline of 44.7% from the February 13th total of 1,020,000 shares. Currently, 2.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VIGL. abrdn plc lifted its stake in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock worth $898,000 after purchasing an additional 293,461 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock valued at $769,000 after buying an additional 66,712 shares during the period. Verition Fund Management LLC acquired a new position in Vigil Neuroscience during the 3rd quarter worth approximately $442,000. Walleye Capital LLC boosted its holdings in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock worth $407,000 after acquiring an additional 92,217 shares during the period. Finally, Point72 Asset Management L.P. grew its position in Vigil Neuroscience by 7.7% in the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock valued at $5,440,000 after acquiring an additional 115,000 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of brokerages recently commented on VIGL. Guggenheim reissued a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. William Blair initiated coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an "outperform" rating for the company. Wedbush lowered their target price on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday. JMP Securities reissued a "market outperform" rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, HC Wainwright reduced their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vigil Neuroscience has an average rating of "Buy" and an average target price of $16.25.

Vigil Neuroscience Stock Down 2.0 %

Shares of VIGL stock traded down $0.04 on Monday, reaching $1.98. 229,830 shares of the stock were exchanged, compared to its average volume of 469,516. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06. The stock has a market cap of $80.94 million, a P/E ratio of -0.96 and a beta of 1.82. The firm has a 50 day moving average of $2.34 and a two-hundred day moving average of $2.78.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). On average, equities research analysts predict that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.